Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Ovid Therapeutics Inc.

    NASDAQ: OVID · Real-Time Price · USD
    0.33
    0.01 (3.58%)
    At close: Jun 09, 2025, 3:59 PM
    3.58%
    Bid 0.3
    Market Cap 23.73M
    Revenue (ttm) 548K
    Net Income (ttm) -24.97M
    EPS (ttm) -0.34
    PE Ratio (ttm) -0.98
    Forward PE -0.48
    Analyst Buy
    Ask 0.36
    Volume 1,083,527
    Avg. Volume (20D) 480,834
    Open 0.33
    Previous Close 0.32
    Day's Range 0.30 - 0.34
    52-Week Range 0.24 - 3.31
    Beta 0.07

    About OVID

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol OVID
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for OVID stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 month ago
    +3.11%
    Ovid Therapeutics shares are trading higher after ... Unlock content with Pro Subscription
    news image

    1 month ago · zacks.com

    Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates

    Ovid Therapeutics (OVID) came out with a quarterly loss of $0.14 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.17 per share a year ago.

    news image

    1 month ago · zacks.com

    Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

    Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    news image

    3 months ago · zacks.com

    Ovid Therapeutics (OVID) Reports Q4 Loss, Lags Revenue Estimates

    Ovid Therapeutics (OVID) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.22 per share a year ago.

    Add to Watchlist